Keymed Biosciences Inc.
2162.HK · HKSE
Market closed81.65-4.30 (-5.00%)
Key statistics
Previous close85.95
Open86.10
Day high88.20
Day low80.35
52-week high89.75
52-week low44.66
Market cap24.05B
Volume4.56M
Average volume2.91M
P/E ratio-38.65
Forward P/E—
EPS-2.11
Dividend yield0.00%
Market context
Why it moved
2162.HK experienced a sharp decline today amid broad sector selling pressure and negative market sentiment, as no specific positive catalysts emerged to support the stock, driving it significantly lower from its previous close.
What is happening
Recent company-specific developments and publisher coverage.
BioWorld News · July 17, 2026Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCsMoomoo · July 16, 2026Keymed Biosciences Expects Return to Profit in H1Latham & Watkins LLP · January 10, 2025Latham Advises Timberlyne Therapeutics on US$180 Million Series A Financing From KeyMed BiosciencesClifford Chance · August 13, 2024Clifford Chance advises Keymed Biosciences Inc. on out-licensing transaction with Belenos Biosciences Mt Newswire · July 16, 2026Keymed Biosciences Expects Return to Profit in H1 Mt Newswire · June 5, 2026Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close Mt Newswire · March 27, 2026Keymed Biosciences' Loss Deepens in 2025 Mt Newswire · March 24, 2026Keymed Biosciences Says Ouro Medicines to be Sold in $2.18 Billion Deal Mt Newswire · March 11, 2026Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%